MD
MDCLF.US MedinCell S.A
- Market cap
- USD 1.24B
- P/E
- -
- P/B
- 320.18x
- ROE
- -1,025.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is MDCLF.US undervalued?
Graham numberThe Graham number of MedinCell S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MedinCell S.A fundamental analysis
No fundamental analysis for MedinCell S.A yet.
MedinCell S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MedinCell S.A
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, whi…
Full company profileMedinCell S.A financial statements
MedinCell S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 8.53M | 6.44M | 1.44M | 2.85M | 8.19M | 4.09M | 9.94M | 9.16M | 25.5M | 24.3M |
| Gross Profit | 7.65M | 6.22M | 434K | 1.88M | 6.74M | 4.09M | 9.94M | 9.16M | 25.5M | 24.3M |
| Operating Income | -3.59M | -7.38M | -15.5M | -19.3M | -15.6M | -23.8M | -24.0M | -21.0M | -10.8M | -25.2M |
| EBITDA | -3.03M | -6.71M | -16.8M | -18.1M | -15.4M | -21.4M | -26.4M | -18.6M | -11.2M | -18.9M |
| Net Income | -3.56M | -9.57M | -19.7M | -23.9M | -19.0M | -24.8M | -32.0M | -25.0M | -18.4M | -31.4M |
| EPS | -0.25 | -0.66 | -1.14 | -1.19 | -0.86 | -1.00 | -1.27 | -0.88 | -0.63 | -0.87 |
| Balance Sheet | ||||||||||
| Total Assets | 23.3M | 25.4M | 38.0M | 27.3M | 63.6M | 44.3M | 29.3M | 36.9M | 90.5M | 108M |
| Total Liabilities | 25.6M | 37.1M | 31.7M | 43.3M | 54.7M | 57.7M | 71.6M | 77.8M | 107M | 105M |
| Shareholders' Equity | -2.33M | -11.8M | 6.24M | -16.0M | 8.92M | -13.4M | -42.3M | -40.8M | -16.4M | 3.06M |
| Cash & Short-term Investments | 8.34M | 8.83M | 21.3M | 12.4M | 49.9M | 26.6M | 6.47M | 19.5M | 71.9M | 84.8M |
| Total Debt | 20.7M | 31.0M | 27.0M | 33.8M | 43.3M | 47.5M | 57.7M | 59.0M | 58.8M | 57.4M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.39M | -5.43M | -15.9M | -12.5M | -12.1M | -21.4M | -21.0M | -11.9M | 19.5M | -24.6M |
| Capital Expenditure | 1.83M | 1.19M | 754K | 921K | 819K | 1.97M | 1.03M | 1.19M | 1.66M | 2.04M |
| Free Cash Flow | -5.22M | -6.61M | -16.7M | -13.5M | -13.0M | -23.3M | -22.0M | -13.1M | 17.8M | -26.6M |
| Ratios | ||||||||||
| ROE | - | - | -315.3% | - | -213.3% | - | - | - | - | -1,025.0% |
| ROA | -15.3% | -37.8% | -51.8% | -87.6% | -29.9% | -56.0% | -109.1% | -67.8% | -20.4% | -29.1% |
| Net Profit Margin | -41.7% | -148.7% | -1,364.3% | -838.5% | -232.3% | -606.5% | -321.9% | -273.3% | -72.2% | -129.4% |
| Debt to Equity | - | - | 4.33x | - | 4.86x | - | - | - | - | 18.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MedinCell S.A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 6.62M | 0.33 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 17.8M | 1.23 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 50:1 on Mar 16, 2017.
Who owns MedinCell S.A
- Insiders 33.97%
- Institutions 32.29%
- Public & others 33.74%
- Shares outstanding 36.0M
- Free float 32.8M
MedinCell S.A company profile
- Company name
- MedinCell S.A
- Ticker
- MDCLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Fiscal year end
- March
- Address
- 3, rue des Frères Lumière, Jacou, France, 34830
- Phone
- 33 4 67 02 13 67
- Website
- medincell.com
About MedinCell S.A
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
MedinCell S.A management
10- Mr. Christophe DouatCEO & Director · born 1966
- Mr. Stephane PosticChief Financial Officer
- Mr. Philippe MoyenChief Operating Officer
- Ms. Julie AlimiGeneral Counsel & Chief Corporate Development Officer
- Mr. David HeuzeHead of Corporate & Financial Communications and ESG
- Mr. Franck PouzacheChief People Officer
- Mr. Adolfo Lopez-NoriegaHead of Research & Development
- Mr. Sebastien EnaultSenior VP & Chief Business Officer
- Ms. Quiterie De BeauregardHead of Global Health Development
- Dr. Grace Kim Ph.D.Chief Strategy Officer of U.S. Finance